Therefore, our current study found that lnc-KASRT promoted osteosarcoma cell viability and mobility; moreover, lnc-KASRT regulated KLF6 alternative splicing to induce KLF6-SV1 while repressing KLF6-WT and regulating P21 and CCND1 expression in osteosarcoma. This evidence concerns the gene KLF6 and osteosarcoma.